ATE430193T1 - Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen - Google Patents

Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen

Info

Publication number: ATE430193T1
Authority: AT; Austria
Prior art keywords: iduronidase; treatment; diseases caused; deficiency diseases; recombinant alpha
Prior art date: 1999-11-12

Application number

AT06011595T

Other languages

English (en)

Inventor

John M Henstrand

Minmin Qin

Wia-Pan Chan

Lin Chen

Paul A Fitzpatrick

Dan J Wendt

Gary N Zecherle

Christopher M Starr

Emil D Kakkis

Becky Tanamachi

Original Assignee

Biomarin Pharm Inc

Los Angeles Biomed Res Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-12

Filing date

2000-11-09

Publication date

2009-05-15

2000-11-09 Application filed by Biomarin Pharm Inc, Los Angeles Biomed Res Inst filed Critical Biomarin Pharm Inc

2009-05-15 Application granted granted Critical

2009-05-15 Publication of ATE430193T1 publication Critical patent/ATE430193T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01014—Chitinase (3.2.1.14)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01075—Glucan endo-1,6-beta-glucosidase (3.2.1.75)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

AT06011595T 1999-11-12 2000-11-09 Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen ATE430193T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/439,923 US6426208B1 (en)	1999-11-12	1999-11-12	Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof

Publications (1)

Publication Number	Publication Date
ATE430193T1 true ATE430193T1 (de)	2009-05-15

Family

ID=23746702

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT06011595T ATE430193T1 (de)	1999-11-12	2000-11-09	Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
AT00993857T ATE342964T1 (de)	1999-11-12	2000-11-09	Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT00993857T ATE342964T1 (de)	1999-11-12	2000-11-09	Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen

Country Status (15)

Country	Link
US (3)	US6426208B1 (de)
EP (2)	EP1332206B1 (de)
JP (3)	JP2004502456A (de)
CN (2)	CN101407796A (de)
AT (2)	ATE430193T1 (de)
AU (2)	AU773663B2 (de)
BR (1)	BRPI0015533B8 (de)
CA (1)	CA2391098C (de)
DE (2)	DE60031456T2 (de)
ES (2)	ES2324727T3 (de)
HK (2)	HK1057059A1 (de)
IL (3)	IL149568A0 (de)
MX (1)	MXPA02004742A (de)
WO (1)	WO2002004616A1 (de)
ZA (1)	ZA200203619B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6585971B1 (en) *	1999-11-12	2003-07-01	Harbor-Ucla Research And Education Institute	Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6569661B1 (en) *	1999-11-12	2003-05-27	Biomarin Pharmaceutical Inc.	Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
EP1368039A4 (de) *	2001-02-20	2006-03-29	Uab Research Foundation	Aminoglycosid-behandlung für lysosomale speicherkrankheiten
US7560424B2 (en)	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US7629309B2 (en)	2002-05-29	2009-12-08	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US7485314B2 (en) *	2002-05-06	2009-02-03	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Induction of antigen specific immunologic tolerance
US20050026823A1 (en) *	2003-06-20	2005-02-03	Biomarin Pharmaceutical Inc.	Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005021716A2 (en) *	2003-08-21	2005-03-10	Q Therapeutics, Inc.	Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders
US7442372B2 (en) *	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
MXPA03011987A (es)	2003-12-19	2005-06-23	Osio Sancho Alberto	Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
WO2007035716A2 (en)	2005-09-16	2007-03-29	Raptor Pharmaceutical Inc.	Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2007065273A1 (en) *	2005-12-08	2007-06-14	The University Of British Columbia	Mucopolysaccharidosis (mps) diagnostic methods, systems, kits and assays associated therewith
ATE539089T1 (de) *	2007-03-21	2012-01-15	Raptor Pharmaceutical Inc	Cyclische rezeptor-assoziierte-proteine (rap)- peptide
EP2188302B1 (de)	2007-07-09	2017-11-01	Genentech, Inc.	Verhinderung der reduktion der disulfidbindung während der rekombinanten herstellung von polypeptiden
EP2093085B1 (de) *	2008-02-21	2012-05-02	Fiat Group Automobiles S.p.A.	Glasstützbaueinheit für eine Kraftfahrzeugtür mit einer ungerahmten oberen Kante
EP3187508A1 (de)	2008-05-07	2017-07-05	BioMarin Pharmaceutical Inc.	Auf lysosomen gerichtete peptide und verwendungen davon
EP2475376B1 (de)	2009-06-17	2016-03-30	BioMarin Pharmaceutical Inc.	Formulierungen für lysosomale enzyme
WO2012101671A1 (en) *	2011-01-25	2012-08-02	Jcr Pharmaceuticals Co., Ltd.	Method for production of human recombinant iduronate 2-sulfatase
DE102011102170B4 (de)	2011-05-20	2024-06-06	Vitesco Technologies GmbH	Einspritzvorrichtung zur Einspritzung eines Fluids
BR112014031788A2 (pt)	2012-06-19	2017-06-27	Univ Florida	composições e métodos para o tratamento de diabetes
US9086580B2 (en)	2012-08-10	2015-07-21	Osio Corporation	Contact lens use in the treatment of an ophthalmologic condition
HUE051373T2 (hu) *	2013-03-15	2021-03-01	Univ Pennsylvania	Készítmények MPSI kezelésére
EP3411488A1 (de)	2016-02-03	2018-12-12	The Trustees Of The University Of Pennsylvania	Gentherapie zur behandlung von mukopolysaccharidose typ i
CA3049915A1 (en) *	2017-01-31	2018-08-09	Stephen YOO	Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
EP3676385A1 (de)	2017-07-06	2020-07-08	The Trustees of The University of Pennsylvania	Aav9-vermittelte gentherapie zur behandlung von mukopolysaccharidose typ i
CA3076036A1 (en)	2017-09-22	2019-03-28	The Trustees Of The University Of Pennsylvania	Gene therapy for treating mucopolysaccharidosis type ii
CN107699590A (zh) *	2017-10-13	2018-02-16	成都中医药大学	一种制备重组人α‑L‑艾杜糖醛酸酶的方法
WO2020132100A1 (en)	2018-12-19	2020-06-25	The Board Of Trustees Of The Leland Stanford Junior University	Bifunctional molecules for lysosomal targeting and related compositions and methods
CN110577559B (zh) *	2019-08-19	2023-02-17	江西科技师范大学	α-L-艾杜糖醛酸酶测定用荧光糖苷酶底物的合成方法
WO2022145449A1 (ja) *	2021-01-04	2022-07-07	国立大学法人徳島大学	ライソゾームを標的とした新規ｄｄｓの開発
CN115109790A (zh) *	2021-03-23	2022-09-27	北京据德医药科技有限公司	一种重组a-L-艾杜糖醛酸普酶及其制备方法
CN114181318B (zh) *	2021-11-08	2023-08-01	四川大学	一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用
CN115161284B (zh) *	2022-07-04	2024-07-09	无锡多宁生物科技有限公司	一种lmh悬浮细胞复苏培养方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL281225A (de)	1961-07-20
GB1029548A (en)	1963-07-17	1966-05-11	Amagasaki Iron & Steel Mfg Co	Corrugated roofing sheet
US3472931A (en)	1969-01-17	1969-10-14	Foster Milburn Co	Percutaneous absorption with lower alkyl amides
US3891757A (en)	1971-11-11	1975-06-24	Alza Corp	Anaesthetic topical and percutaneous administration with selected promoters
US5270051A (en)	1991-10-15	1993-12-14	Harris Donald H	Enzyme-orthokeratology
US6149909A (en) *	1995-06-23	2000-11-21	Women's And Children's Hospital	Synthetic α-L-iduronidase and genetic sequences encoding same
CA2099503C (en)	1991-11-14	2007-10-09	Hamish Steele Scott	Synthetic alpha-l-iduronidase and genetic sequences encoding same
US5278051A (en) *	1991-12-12	1994-01-11	New York University	Construction of geometrical objects from polynucleotides
EP0865499B1 (de)	1995-09-14	2009-03-18	Virginia Tech Intellectual Properties, Inc.	Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen
GB9807464D0 (en)	1998-04-07	1998-06-10	Pharming Bv	Purification of human acid µ-glucosidase
EP1078075A2 (de)	1998-05-13	2001-02-28	Harbor-Ucla Research and Education Institute	Rekombinante (alpha)-l-iduronidase, deren herstellungs- und aufreinigungs-verfahren, und verfahren zur behandlung von durch diese hervorgerufene mangelerkrankungen

1999
- 1999-11-12 US US09/439,923 patent/US6426208B1/en not_active Expired - Lifetime
2000
- 2000-11-09 ES ES06011595T patent/ES2324727T3/es not_active Expired - Lifetime
- 2000-11-09 WO PCT/US2000/031293 patent/WO2002004616A1/en active IP Right Grant
- 2000-11-09 CN CNA2008101440588A patent/CN101407796A/zh active Pending
- 2000-11-09 DE DE60031456T patent/DE60031456T2/de not_active Expired - Lifetime
- 2000-11-09 AT AT06011595T patent/ATE430193T1/de not_active IP Right Cessation
- 2000-11-09 AT AT00993857T patent/ATE342964T1/de not_active IP Right Cessation
- 2000-11-09 JP JP2002509470A patent/JP2004502456A/ja not_active Withdrawn
- 2000-11-09 ES ES00993857T patent/ES2273748T3/es not_active Expired - Lifetime
- 2000-11-09 CA CA002391098A patent/CA2391098C/en not_active Expired - Lifetime
- 2000-11-09 DE DE60042137T patent/DE60042137D1/de not_active Expired - Lifetime
- 2000-11-09 CN CN008181705A patent/CN1420924B/zh not_active Expired - Lifetime
- 2000-11-09 MX MXPA02004742A patent/MXPA02004742A/es active IP Right Grant
- 2000-11-09 AU AU84635/01A patent/AU773663B2/en not_active Expired
- 2000-11-09 EP EP00993857A patent/EP1332206B1/de not_active Expired - Lifetime
- 2000-11-09 IL IL14956800A patent/IL149568A0/xx unknown
- 2000-11-09 EP EP06011595A patent/EP1792983B1/de not_active Expired - Lifetime
- 2000-11-09 BR BRPI0015533A patent/BRPI0015533B8/pt not_active IP Right Cessation
2002
- 2002-05-07 ZA ZA200203619A patent/ZA200203619B/en unknown
- 2002-05-09 IL IL149568A patent/IL149568A/en active IP Right Grant
- 2002-07-25 US US10/206,443 patent/US7041487B2/en not_active Expired - Lifetime
2003
- 2003-12-22 HK HK03109319A patent/HK1057059A1/xx not_active IP Right Cessation
2004
- 2004-08-23 JP JP2004242343A patent/JP3857705B2/ja not_active Expired - Lifetime
- 2004-09-03 AU AU2004208651A patent/AU2004208651A1/en not_active Abandoned
2006
- 2006-05-05 US US11/429,422 patent/US20060286087A1/en not_active Abandoned
- 2006-08-07 JP JP2006215076A patent/JP2006312648A/ja active Pending
2007
- 2007-11-30 HK HK07113088.9A patent/HK1104836A1/xx not_active IP Right Cessation
2008
- 2008-06-11 IL IL192078A patent/IL192078A/en active IP Right Grant

Also Published As

Publication number	Publication date
ZA200203619B (en)	2003-07-30
DE60042137D1 (de)	2009-06-10
BR0015533A (pt)	2002-06-25
IL149568A0 (en)	2002-11-10
US6426208B1 (en)	2002-07-30
ES2273748T3 (es)	2007-05-16
DE60031456T2 (de)	2007-08-23
EP1332206B1 (de)	2006-10-18
CN1420924A (zh)	2003-05-28
CN1420924B (zh)	2010-05-05
WO2002004616A1 (en)	2002-01-17
IL149568A (en)	2010-04-29
US20060286087A1 (en)	2006-12-21
AU2004208651A1 (en)	2004-09-30
IL192078A (en)	2011-06-30
JP3857705B2 (ja)	2006-12-13
CA2391098C (en)	2007-10-23
BRPI0015533B8 (pt)	2021-05-25
JP2005046154A (ja)	2005-02-24
AU8463501A (en)	2002-01-21
EP1792983A1 (de)	2007-06-06
BRPI0015533B1 (pt)	2020-12-08
IL192078A0 (en)	2008-12-29
CA2391098A1 (en)	2002-01-17
EP1332206A1 (de)	2003-08-06
AU773663B2 (en)	2004-06-03
MXPA02004742A (es)	2005-09-08
DE60031456D1 (de)	2006-11-30
HK1104836A1 (en)	2008-01-25
EP1792983B1 (de)	2009-04-29
JP2006312648A (ja)	2006-11-16
ATE342964T1 (de)	2006-11-15
JP2004502456A (ja)	2004-01-29
HK1057059A1 (en)	2004-03-12
ES2324727T3 (es)	2009-08-13
CN101407796A (zh)	2009-04-15
US20030013179A1 (en)	2003-01-16
US7041487B2 (en)	2006-05-09

Publication	Publication Date	Title
ATE430193T1 (de)	2009-05-15	Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
ATE501722T1 (de)	2011-04-15	Therapeutische behandlung androgenrezeptorbedingter leiden
IL143313A0 (en)	2002-04-21	Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases
DE69826695D1 (de)	2004-11-04	Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE381935T1 (de)	2008-01-15	Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
EP1390491A4 (de)	2005-04-06	Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
ATE355374T1 (de)	2006-03-15	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE202940T1 (de)	2001-07-15	Mittel und methoden zur behandlung von plaque- krankheiten
ATE207356T1 (de)	2001-11-15	Verwendung von tiagabin zur behandlung von schlafstörungen
BR0011251A (pt)	2002-03-05	Composições de a-beta peptìdeo e processos para a produção das mesmas
ATE311853T1 (de)	2005-12-15	Verwendung von krillenzymen zur behandlung von zahnbelag
EA200001247A1 (ru)	2001-08-27	N-связанные сульфонамиды n-гетероциклических карбоновых кислот или изостеры карбоновых кислот
ATE291927T1 (de)	2005-04-15	Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
DE60221283D1 (de)	2007-08-30	Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
DE60008753D1 (de)	2004-04-08	Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE85523T1 (de)	1993-02-15	Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
BR9910323A (pt)	2001-01-30	Alfa-l-iduronidase recombinante, métodos para produção e purificação da mesma e métodos para tratamento de doenças ocasionadas deficiência da mesma
ATE217191T1 (de)	2002-05-15	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
WO2004043373A3 (en)	2004-08-05	Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
TR200200278T2 (tr)	2002-06-21	Kalsilitik bileşimler
ATE534399T1 (de)	2011-12-15	Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
ATE299024T1 (de)	2005-07-15	Purin-2,6-dione als inhibitoren des enzyms dipeptidyl-peptidase iv (dpp-iv)
ATE498397T1 (de)	2011-03-15	Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen
DE60020970D1 (de)	2005-07-28	Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
DE60108241D1 (de)	2005-02-10	Felabamat-derivate zur behandlung von neuropathischem schmerz

Legal Events

Date	Code	Title	Description
2009-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties